TCRX Stock News & Analysis | Latest Updates

TScan Therapeutics to Participate in Upcoming Investor Conferences

(NASDAQ:TCRX) WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

September 3, 2025Events

TCRX News

TScan Therapeutics to Participate in Upcoming Investor Conferences

What Analysts Are Saying About TScan Therapeutics Stock

HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10

TScan Therapeutics Q1 EPS $(0.26) Beats $(0.29) Estimate, Sales $2.17M Beat $1.10M Estimate

TScan Therapeutics To Present At The American Society Of Gene And Cell Therapy 28th Annual Meeting

Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts

Needham Reiterates Buy on TScan Therapeutics, Maintains $9 Price Target

Barclays Maintains Overweight on TScan Therapeutics, Lowers Price Target to $3

Breaking Down TScan Therapeutics: 4 Analysts Share Their Views

HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target

Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $9

TScan Therapeutics Q4 2024 GAAP EPS $(0.30) Misses $(0.27) Estimate, Sales $665.00K Miss $1.35M Estimate, Cash, Cash Equivalents, And Marketable Securities Of $290.1M To Fund Operations Into Q1 Of 2027

HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target

Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews

Needham Reiterates Buy on TScan Therapeutics, Maintains $11 Price Target

TScan Therapeutics Announces Oral Presentation Of Data From ALLOHA Phase 1 Heme Trial At 66th ASH Annual Meeting

BTIG Initiates Coverage On TScan Therapeutics with Buy Rating, Announces Price Target of $12